The use of fluoroquinolones for companion animal antimicrobial therapy

Australian Veterinary Journal

Volumn 78, Issue 2, 2000, Pages 84-90

  Walker, R D ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ANIMAL; ANIMAL DISEASE; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BIRD DISEASE; CAT; CAT DISEASE; CATTLE; CATTLE DISEASE; CHEMISTRY; DOG; DOG DISEASE; DOMESTIC ANIMAL; MICROBIOLOGICAL EXAMINATION; POULTRY; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANIMALS, DOMESTIC; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; CAT DISEASES; CATS; CATTLE; CATTLE DISEASES; DOG DISEASES; DOGS; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; POULTRY; POULTRY DISEASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034133493     PISSN: 00050423     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1751-0813.2000.tb10528.x     Document Type: Article

References (23)

1. Drusano GL, Johnson DE, Rosen M. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993;37:483-490.
2. Kaatz GW, Barriere SL, Schaberg DR et al. The emergence of the resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis. J Antimicrob Chemother 1987;20:753-758.
3. Blaser J, Stone BB, Groner MC et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bacterial activity and emergence of resistance. Antimicrob Agents Chemother 1987;31: 1054-1060.
4. Stein GE. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin Infect Dis 1996;23 (Suppl 1):S19-24.
5. Stein GE. The newer fluoroquinolones. Pharmacoeconomics: infectious diseases, 2nd quarter 1998, Vol II.
6. Forrest A, Nix DE, Ballow CH. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073-1081.
7. Preston SL, Drusano GL, Berman AL et al. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob Agents Chemother 1998;42:1098-1104.
8. Hooper DC, Wolfson JS. Quinolone antimicrobial agents, 2nd edn. American Society for Microbiology, Washington, 1993.
9. Androile VT. The quinolones, 2nd edn. Academic Press, San Diego, 1998.
10. Kuhlmann J, Dalhoff A, Zeiler HJ, editors. Quinolone antibacterials. Handbook of experimental pharmacology, Vol 127. Springer-Verlag, Berlin, 1998.
11. Schentag JJ, Scully BE. Quinolones. In: Yu VL, Merigan TC, Barriere SL, editors. Antimicrobial therapy and vaccines. Williams and Wilkins, New York, 1999:875-901.
12. Walker RD, Stein GE, Hauptman JG et al. Serum and tissue cage fluid concentrations of ciprofloxacin after oral administration of the drug to healthy dogs. Am J Vet Res 1990;51:896-900.
13. Walker RD, Stein GE, Hauptman JG et al. Pharmacokinetic evaluation of enrofloxacin administered orally to healthy dogs. Am J Vet Res 1992;53:2315-2319.
14. Goldstein EJC, Citron DM, Hudspeth M et al. Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens. J Antimicrob Chemother 1998;391-396.
15. Walker RD, Thornsberry C. Decrease in antibiotic susceptibility or increase in resistance? J Antimicrob Chemother 1998;41:1-4.
16. National Committee on Clinical Laboratory Standards. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; Approved Standard. 1999. NCCLS Document M31-A. Wayne, Pennsylvania.
17. Craig WA. Pharmacokinetic/ pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. State-of-the-art clinical article. Clin Infect Dis 1998;26:1-12.
18. Craig WA, Gudmundsson S. Post antibiotic effect. In: Lorian V, editor. Antibiotics in laboratory medicine, 4th edn. Williams and Wilkins, Baltimore, 1996:403-321.
19. Thomas JK, Forrest A, Bhavnami SM et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998;42:521-527.
20. Craig W, Dalhoff A. Pharmacodynamics of fluoroquinolones in experimental animals. In: Kuhlmann J, Dalhoff A, H.-J. Zeiler, editors. Quinolone antibacterials. Springer-Verlag, Berlin, 1998:207-232.
21. Schneider M, Thomas V, Boisrame B et al. Pharmacokinetics of marbofloxacin in dogs after oral and parenteral administration. J Vet Pharmacol Therap 1996;19:56-61.
22. Watts JL, Salmon SA, Sanchez MS et al. In vitro activity of premafloxacin, a new extended-spectrum fluoroquinolone, against pathogens of veterinary importance. Antimicrob Agents Chemother 1997;41:1190-1192.
23. Stegemann M, Heukamp, U, Scheer M et al. Kinetics of antibacterial activity after administration of enrofloxacin in dog serum and skin: in vitro susceptibility of field isolates. Compend Contin Educ Pract Vet 1996;18(Suppl):30-34.